Celecoxib, a cyclooxygenase-2 (COX-2) selective inhibitor, is a prospective alternative for the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis [1]. This evidence concerns the gene PTGS2 and ankylosing spondylitis.